BLFS

BioLife Solutions Inc

BioLife Solutions Inc manufactures proprietary and generic cGMP biopreservation media products, generic formulations of blood stem cell freezing media products, custom product formulation packaging services and contract aseptic manufacturing formulation.

BioLife Solutions Inc (BLFS) is rated C+ (2.5/5) on Deltasharpe Prism, scored against Healthcare sector peers. Its strongest pillar is Profitability (B-); its weakest is Value (D+).

Quantitative Factor Evaluation • Updated

Overall Rating
2.5 / 5.0
C+
Value
D+
Factor Score 1.8 / 5.0
Growth
C+
Factor Score 2.7 / 5.0
Profitability
B-
Factor Score 2.9 / 5.0
Momentum
C+
Factor Score 2.5 / 5.0
Revisions
C+
Factor Score 2.6 / 5.0

Prism grades are automated quantitative screens, not buy, sell or hold recommendations, and not investment advice. Data may be delayed or contain errors. Terms

Ratings of B- and above are for members.

Register free to see every rating — your first 2 weeks of Premium are on us.

Register — 2 weeks free

Underlying Financial Metrics

P/E Ratio 39.0
EV / EBITDA 264.0
Rev Growth YoY 21.5%
Gross Margin 63.6%
Price Return 3M N/A
Price Return 12M N/A
Catalyst Signal 0.00
Market Cap $1.9B
TTM Revenue $106.7M
Price / Sales 17.7
ROE 12.8%

Historical Factor Score Progression

Date Value Growth Profitability Momentum Revisions Overall
2026-11-17 D+ (1.8) C+ (2.7) B- (2.9) C+ (2.5) C+ (2.6) C+ (2.5)
2026-11-10 D+ (1.8) C+ (2.7) B- (2.9) C+ (2.5) C+ (2.6) C+ (2.5)
2026-11-03 D+ (1.8) C+ (2.7) B- (2.9) C+ (2.5) F (0.0) C- (2.0)
2026-10-27 D+ (1.8) C+ (2.6) B- (2.9) C+ (2.5) F (0.0) C- (2.0)
2026-10-20 D+ (1.8) C+ (2.6) B- (2.9) C+ (2.5) F (0.0) C- (2.0)
Page 1 of 4